SKIN VACCINATION SUMMIT 2017
22-24 May 2017, Leiden University Medical Centre, Leiden, The Netherlands

FINAL ORAL & POSTER PROGRAMME

SVS 2017

SCIENTIFIC ADVISORY PANEL

SVS 2017 Chairperson:
Joke Bouwstra (Leiden/Amsterdam Center for Drug Research, The Netherlands)

Bruce G. Weniger (Chiang Mai University, Chiang Mai, Thailand)
Mark Kendall (University of Queensland, Australia)
Richard Companos (Emory University, Atlanta, Georgia, USA)
Behazine Combadiere (INSERM, Paris, France)
Niranjan Y. Sardesai (INOVO Inc., Plymouth Meeting, Pennsylvania, USA)
Mark Tomai (3M Drug Delivery Systems, St. Paul, Minnesota, USA)
Darin Zehrung (PATH, Seattle, Washington, USA)
Yotam Levin (NanoPass Technologies Ltd, Rehovot, Israel)
Nathalie Garcon (Bioaster, Lyon, France)
Mark Prausnitz (Georgia Institute of Technology, Atlanta, USA)
Ryan Donnelly (Queen's University Belfast, Northern Ireland, UK)
Terry L. Bowersock (Zoetis Inc., Kalamazoo, Michigan, USA)
Michael Royals (Independent Consultant, Denver, Colorado, USA)
John Clements (Tulane University, New Orleans, Louisiana, USA)
Derek O’Hagan (GSK, Cambridge, Massachusetts, USA)
Steve Reed (IDRI, Seattle, Washington, USA)
Anne Moore (University of Cork, Cork, Ireland)
Marcel B.M. Teunissen (University of Amsterdam, Amsterdam, The Netherlands)
Izzy Tsals (SID Technologies LLC, Newtown, Pennsylvania, USA)
Laurent-Dominique Piveteau (Debiotech SA, Lausanne, Switzerland)
Bobby Singh (Corium International, Menlo Park, California, USA)
Cees W.J. Oomens (Eindhoven University of Technology, Eindhoven, The Netherlands)
Claus-Michael Lehr (Helmholtz Center for Infection Research (HZI), Saarland University, Saarbrücken, Germany)
Esther de Jong (University of Amsterdam, Amsterdam, The Netherlands)
Ferry A. Ossendorp (Leiden University Medical Center, Leiden, The Netherlands)
Maria G. Isaguliants (Karolinska Institute, Stockholm, Sweden)
08.15  
Arrival & Registration & Poster-Set-Up
09.20-09.30  
Welcome to Leiden
Joke Bouwstra
(Leiden/Amsterdam Center for Drug Research, Amsterdam, The Netherlands)

SESSION 1: OPENING PLENARY SESSION

Moderator: Joke Bouwstra
(Leiden/Amsterdam Center for Drug Research, Amsterdam, The Netherlands)
09.30-10.00  
‘How can skin be utilized for improved vaccines?’
Mark Kendall
(University of Queensland, Brisbane, Queensland, Australia)
10.00-10.30  
‘Immunotherapy of cancer’
Ferry Ossendorp
(Leiden University Medical Centre, Leiden, The Netherlands)
10.30-11.00  
‘Can skin vaccination be beneficial for pregnancy?’
(Emory University, Atlanta, Georgia, USA)
11.00-11.30  
Coffee Break & Poster Set-Up

SESSION 2: PLENARY

Moderator: Mark Kendall
(University of Queensland, Brisbane, Queensland, Australia)
11.30-12.00  
‘Migration of cells using human skin models’
Esther de Jong
(University of Amsterdam, Amsterdam, The Netherlands)
12.00-12.30  
‘Role of tissue-resident memory T cells in protective immunity: Implications for vaccination’
Marcel B.M. Teunissen
(University of Amsterdam, Amsterdam, The Netherlands)
12.30-13.00  
‘Modelling of uptake and trafficking of DCs’
Cees W.J. Oomens
(Eindhoven University, Eindhoven, The Netherlands)
13.00-14.30  
Lunch Break & Posters

SESSION 3: SKIN TOPICS

Moderator: Marcel B.M. Teunissen
(University of Amsterdam, Amsterdam, The Netherlands)
14.30-15.00  
‘Synergistic effects of dendritic cell targeting and laser-microporation on enhancing epicutaneous skin vaccination efficacy’
Richard Weiss
(University of Salzburg, Salzburg, Austria)
15.00-15.20  
‘Sialic Acid receptors and Langerin on Langerhans cells in a human skin model for vaccination strategies against melanoma’
J. Lübbers, S. Duinkerken, R.J.E. Li, J.J. Garcia-Vallejo and Y. van Kooyk
(VU University Medical Center, Amsterdam, The Netherlands)
15.20-15.40  
‘Development of a vaccination strategy targeting human skin DC using tumor specific glyco-conjugates’
S. Duinkerken, C.M. Fehres, H. Kalay, M. Ambrosini, S.J. van Vliet, J.J. Garcia-Vallejo and Y. van Kooyk
(VU University Medical Center, Amsterdam, The Netherlands)
15.40-16.00  
‘Which skin model is best for dermal drug delivery?’
Lisa A. Dick, Scott A. Burton, Vinh S. Hua and Joan M. Moseman
(3M Drug Delivery Systems, St. Paul, Minnesota, USA)
16.00-16.30  
Tea Break & Posters

SESSION 4: MICRONEEDLES/MICROARRAYS I

Moderator: Mark Prausnitz
(Georgia Institute of Technology, Atlanta, Georgia, USA)
16.30-17.00  
‘Diphtheria toxoid coated microneedles for intradermal vaccination’
Joke Bouwstra
(Leiden/Amsterdam Center for Drug Research, Amsterdam, The Netherlands)
17.00-17.20  
‘Examining the breadth of use of dissolvable microneedle patches for dermal delivery of polio vaccines’
Anne Moore
(University College Cork, Cork, Ireland)
17.20-17.40  
‘Polymeric microneedle arrays as intradermal vaccination candidates: Making the right choices’
A.J. Courtenay, M.T.C. McCrudden and R.F. Donnelly
(Queens University Belfast, Belfast, Co. Antrim, Northern Ireland, UK)
17.40-18.00  
‘Technical approaches for microneedle-based dermal vaccine delivery’
K. van der Maaden, W. Jiskoot and J. Bouwstra
(Leiden Academic Centre for Drug Research (LACDR), Leiden University, The Netherlands)
18.00-19.00  
SVS 2017 Welcome Drinks Reception & Poster Session

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.
SESSION 5: DELIVERY I

Moderator: Yotam Levin (NanoPass Technologies Ltd, Nes Ziona, Israel)
09.00-09.20
‘New trends in ID Vaccination: From prophylaxis to immunotherapy and beyond’
Yotam Levin and Efrat Kochba (NanoPass Technologies, Nes Ziona, Israel)

09.20-09.50
‘Assessing the health impact of vaccine delivery technologies: A quantitative tool’
Darin Zehrung and Mercy Mvundura (PATH, Seattle, Washington, USA)

09.50-10.20
‘Nanoparticulate delivery and targeting via the hair follicles’
Claus Michael Lehr (Heilmann-Zentrum für Infektionsforschung GmbH, Braunschweig, Germany)

10.20-10.40
‘Needle adapters and needle-free injectors for intradermal administration of fractional dose of inactivated poliovirus vaccine: Pilot polio eradication campaigns in Pakistan’
Ondrej Mach (World Health Organization, Geneva, Switzerland)

10.40-11.00
‘Novel electroporation technology enhances gene delivery to the skin’
Kate E. Broderick and Jean Boyer (Inovio Pharmaceuticals, San Diego, California, USA)

11.00-11.15
Coffee Break & Posters

SESSION 6: MICRONEEDLE PATCHES

Moderator: Darin Zehrung (PATH, Seattle, Washington, USA)
11.15-11.30
‘The public health value proposition of novel delivery technologies: Building policies for procurement and uptake’
Birgitte Giersing and Martin Friede (WHO, Geneva, Switzerland)

11.30-11.50
‘First-time-in-human clinical trials evaluating the acceptability and tolerability of high-density silicon microarray patches (the Nanopatch)’
Angus Forster1, Cristyn Davies2, Rachel Skinner3, Samantha Brandler4 and Paul Griffin5,6 (1 Vaxxas Pty Ltd, Brisbane, Australia; 2 University of Sydney, Sydney, Australia; 3 360 biolabs, Melbourne, Australia; 4 Mater Health Services and Mater Medical Research Institute, Brisbane, Australia; 5 Q-Pharm, Herston, Australia)

11.50-12.20
‘Translation of microneedle patch vaccines from laboratory to clinic’
Mark Prausnitz (Georgia Institute of Technology, Atlanta, Georgia, USA)

12.20-12.40
‘Delivery of trivalent influenza vaccine with microneedle patches shows rapid and enhanced antibody gene expression in vaccines’
Lisa K. Milla1, E. Stein Esser1, Elena V. Vassilieva1, Richard W. Compa1 ns1, Ioanna Skountzou1, Sebastien Henry2, Devin McAllister3, Haripriya Kalluri4, Winston Pewin5, Mark R. Prausnitz6, Nadine Rouphael7, Mark J. Mulligan8 and the TV-MNP2015 Study Group9 (1 Emory University School of Medicine, Atlanta, Georgia, USA; 2 School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA; 3 Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA; 4 Materials and Engineering Research Institute, Georgia Institute of Technology, Atlanta, Georgia, USA; 5 Emory University School of Medicine, Atlanta, Georgia, USA; 6 Georgia Institute of Technology, Atlanta, Georgia, USA; 7 Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Emory University, Atlanta, Georgia, USA; 8 Georgia Institute of Technology, Atlanta, Georgia, USA; 9 TV-MNP2015 Study Group)

12.40-13.00
‘A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines’
Wandi Zhu1, Mark R. Prausnitz2 and Bao-Zhong Wang1 (1 Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA; 2 School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA)

13.00-14.20
Lunch Break & Posters

SESSION 7: MICRONEEDLES/MICROARRAYS II

Moderator: Mark Kendall (University of Queensland, Brisbane, Queensland, Australia)
14.20-14.40
‘Skin vaccination using a microneedle patch induces mucosal immunity to rotavirus in mice’
Theresa K. Reschi1, Yuhuan Wang2, Sung-Sil Moon3, Jessica Joyce4, Song Li5, Mark Prausnitz2 and Baoming Jiang6 (1 Division of Viral Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA; 2 School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA)

14.40-15.00
‘High protein content in dissolving microneedles for dermal vaccine delivery’
M. Leone1, M.I. Priester1, J. Mönkäre1, C. O’Mahony1, J.A. Bouwstra1 and G. Kersten2 (1 LACDR, Leiden University, The Netherlands; 2 Intravacc, Biltoven, The Netherlands; 3 Tyndall National Institute, Cork City, Ireland)

15.00-15.20
‘The use of solid and hollow microneedle systems for administration of prophylactic and therapeutic vaccines’
Mark Tomai (3M Company, St. Paul, Minnesota, USA)

15.20-15.40
‘Cellular responses after hollow microneedle immunization: Comparative study of ovalbumin-loaded nanoparticles’

15.40-16.00
‘Acceptability, usability, and programmatic fit of microarray patches for vaccine delivery in Ghana’
Sarah McGraw1, Charlotte Tawiah2, Courtney Jarrahian3 and Darin Zehrung4 (1 PATH, Seattle, Washington USA; 2 Kintampo Health Research Centre (KHRC) Ghana Health Services, Kintampo, Brong Ahafo Region, Ghana)

16.00-16.30
Tea Break & Posters

SESSION 8: ADJUVANTS & VACCINES

Moderator: Yotam Levin (NanoPass Technologies, Nes Ziona, Israel)
16.30-16.50
‘Polyfunctional Type 1 T cells induced by NanoPass intradermal delivery of LAMP-based vaccines: A potential for nucleic acid based cancer vaccines’
Teri Heiland (Immunometric Therapeutics Inc., Rockville, Maryland, USA)

16.50-17.10
‘New vaccine based on Antigen1 against leishmaniasis’
Alessandra Marcia da Fonseca Martins and Herbert Leonel de Matos Guedes (Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil)

17.10-17.30
‘Thermosetable plasmid DNA launches a live-attenuated yellow fever vaccine platform that targets dendritic cells in the dermis and induces protection in vivo’
Michael A. Schmid, Niraj Mishra, Johan Neyts and Kai Dallmeier (Rega Institute for Medical Research KU Leuven, University of Leuven, Leuven, Belgium)
SESSION 9: DELIVERY II

Moderator: Mark Tornai (GM Company, St. Paul, Minnesota, USA)
09.00-09.20
‘Overview of development of microneedle patches with Inactivated Poliovirus Vaccine (IPV)’
Shanda Boyle and Hiromasa Okayasu
(! Bill & Melinda Gates Foundation, Seattle, Washington, USA; 2 Polio Eradication Department, World Health Organization, Geneva, Switzerland)
09.20-09.50
‘Transitioning delivery of inactivated poliovirus vaccine by the Nanopatch from pre-clinical studies to clinical trials’
David A. Muller, Germán Fernández, Paul R. Young, Paul Fahey and Angus Forster
(! Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia; 2 School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia; 3 Vaxxas Pty Ltd, Sydney, New South Wales, Australia)
09.50-10.20
‘HIV enzyme interactions in combined intradermal DNA immunization in mice’
Maria G. Isaguliants,1,2,3
(1 A. Kirchenstein Institute of Microbiology and Virology, Riga Stradins University (RSU), Riga, Latvia; 2 Chumakov Federal Scientific Center for Research and Development of Immunobiological Preparations, Moscow, Russia; 3 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden)
10.20-10.50
‘Tracking nanoparticles from top to the bottom: Uptake behavior of Chitosan–PLGA nanoparticles within the skin structure’
Hanzey Yasar, Simon Delandre, Chiara De Rossi, Kai Schulze, Brigitta Loretz, Sarah Gordon, Andreas Müller, Carlos A. Guzman and Claus-Michael Lehr
(1 Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) and Helmholtz Centre for Infection Research (HZI), Department of Drug Delivery, Saarbruecken, Germany; 2 Helmholtz Centre for Infection Research (HZI), Department of Vaccinology and Applied Microbiology, Braunschweig, Germany; 3 School of Pharmacy and Biomolecular Sciences, James Parsons Building Tower, Byrom Street, Liverpool, UK; 4 Otto-von-Guericke University of Magdeburg (OVGU), Magdeburg, Germany)
10.50-11.30
Coffee Break & Posters

SESSION 10: DELIVERY III

Moderator: Anne Moore (University College Cork, Cork, Ireland)
11.30-11.50
‘Tight junction inhibition as a transdermal vaccine delivery strategy’
Matthew G Brewer, Elizabeth Anderson, Benjamin Miller and Lisa Beck
(University of Rochester, Rochester, New York, USA)
11.50-12.10
‘Prophylactic intradermal delivery of INO-4201 drives robust ebola glycoprotein specific humoral and cellular Immune responses in healthy volunteers in an open label phase I trial’
Jean Boyer and Kate E. Broderick
(Inovo Pharmaceuticals, San Diego, California, USA)
12.10-12.30
‘Importance of assessment of skin thickness in healthy children aged 8 weeks to 18 years in development of intraderal drug delivery devices’
Timothi Van Mulder (Novosanis NV, Wijlegem, Belgium)
12.30-14.00
Lunch Break & Posters Breakdown

SESSION 11: LATE-BREAKER PRESENTATIONS

Moderators: Jake Bouestra and Bram Slutter
(Leiden/Amsterdam Center for Drug Research, Amsterdam, The Netherlands)
14.00-14.40
‘Role of alternative reading frame protein in the immune response to HCV core, evaluation by intradermal DNA-immunization in mice’
Juris Jansons,1,2, Anastasija Dobrienska,3 Dace Skrastina,4 Stefan Petrov,4 Elizaveta Stanodubova,1,2,5 Yulia Kuzmenko,6 Gatis Akmankalns,6 Maria G. Isaguliants,1,2,3 and Irina Sominskaya
(1 Riga Stradins University, Riga, Latvia; 2 Latvian Biomedical Research and Study Center, Riga, Latvia; 3 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; 4 WA Engelhardt Institute of Molecular Biology, Moscow, Russia; 5 Chumakov Institute of Polymyelitis and Viral Encephalitides, Moscow, Russia; 6 Gamaleya Research Center of Epidemiology and Microbiology, Moscow, Russia)
14.40-14.50
‘Tuberculin skin test (TST) using dissolving microneedle fabricated by centrifugraphy’
Hyungil Jung (Yonsei University, Seoul, Korea)
14.50-15.00
‘Experimental vaccine protects against hepatitis E virus genotypes 1 and 3 in non-human primate model’
Ilya V. Gordeychuk,1,2 Allexey M. Chumakov,3 Anna A. Lyashenko,3 Alexey A. Sorokin,4 Stanislav A. Gulyaev,1,2 Ilya A. Potemkin,5 Amir I. Tukhvatulin,6 Denis Y. Logunov,4 Anastasia A. Karltef,6 Olga V. Isava,7 Karen K. Kyuregyan7 and Mikhail I. Mikhailov
(1 Chumakov Federal Scientific Center for Research and Development of Immuno-and-Biological Products of the Russian Academy of Sciences, Moscow, Russia; 2 Gamaleya Research Center for Epidemiology and Microbiology, Ministry of Healthcare of the Russian Federation, Moscow, Russia; 3 Research center at Russian Medical Academy of Postgraduate Education, Ministry of Healthcare of the Russian Federation, Moscow, Russia)
15.00-15.15
‘Alternative reporters for monitoring the success of intradermal DNA delivery and expression in a mouse model’
Laura Hippe,1 Martins Kalsi,1 Ilya Gordeychuk,2,3 Stefan Petrov,4 Maxim Abakumov,4 Daria Schcherbakova,4 Vladislav Verkhusha4 and Maria G. Isaguliants1,2,3
(1 A. Kirchenstein Institute of Microbiology and Virology, Riga Stradins University (RSU), Riga, Latvia; 2 Chumakov Federal Scientific Center for Research and Development of Immunobiological Preparations, Moscow, Russia; 3 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; 4 The Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia; 5 Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, New York, USA)
15.15-15.30
‘Administration of different Toll like receptor agonists by dissolving microneedle patches to pigs: Assessment of local immune response by macroscopic and histologic evaluation’
Sandra Vreman,1 Joanne McCaffrey2, Norbert Stockhofe-Zurwieden3 and Anne Moore4
(1 Wageningen Bio veterinary Research, Wageningen University & Research, The Hague, The Netherlands; 2 Xenos, Pharmaceuticals, Dublin, Ireland; 3 School of Pharmacy University College Cork, Cork, Ireland)
15.30-15.45
‘Stable expression of HIV reverse transcriptase by murine adenocarcinoma cells enhances growth rate of primary tumors in a mouse model designed to test the therapeutic efficacy of HIV DNA vaccines’
E. Pankova,1,2 A. Latanova1,2,3 A. Kilpelainen1,4 I. Gordeychuk,1,2,5 S. Petkov,1 M. Abakumov,1 E. Starodubova,1,2,3,5 and M. Isaguliants1,2,3,6
(1 Engelhardt Institute of Molecular Biology, Moscow, Russia; 2 Gamaleya Research Center of Epidemiology and Microbiology, Moscow, Russia; 3 Karolinska Institutet, Stockholm, Sweden; 4 Pirogov Medical State University, Moscow, Russia; 5 Chumakov Federal Scientific Center for Research and Development of Immuno-and-Biological Products of the Russian Academy of Sciences, Moscow, Russia; 6 Riga Stradins University, Riga, Latvia)
15.45
Conference Close & Departure
Poster 101
‘Intradermal vaccination with hollow microneedles: Comparative study of protein antigen encapsulated in nanoparticles’
G.S. Du¹, J. Mönkäre¹, J. Tu², R. Nejadnik¹, A. Kros², W. Jiskoot¹ and J.A. Bouwstra¹
(¹ Leiden Academic Center for Drug Research; ² Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands)

Poster 102
‘Development of dissolvable microneedle patches for dermal delivery of polio vaccines’
Agneze Donadel³, Olga Ophorst³, Rimko Ten Have³, Heleen Kraan³, Olivia Flynn¹, Ivo Ploemen¹ and Anne Moore³
(³ School of Pharmacy, University College Cork, Cork, Ireland; ² Institute of Translational Vaccinology (Intravacc), Bilthoven, Netherlands)

Poster 103
‘Alternative reporters for monitoring the success of intradermal DNA delivery and expression in a mouse model’
Laura Hippe¹, Kalis Martins¹ and Maria G. Isaguliants²
(¹ A.Kirchenstein Institute of Microbiology and Virology (AKMVI), Riga Stradins University, Riga, Latvia; ² Karolinska Institutet, Stockholm, Sweden)

Poster 104
‘Stable expression of HIV reverse transcriptase by murine adenocarcinoma cells enhances growth rate of primary tumors in a mouse model designed to test the therapeutic efficacy of HIV DNA vaccines’
E. Pankova¹,², A. Latanova¹,², A. Kipelainen¹,², I. Gordeychuk²,³, S. Petkov³, M. Abakumov⁴, E. Starodubova²,³,⁵ and M. Isaguliants²,³,⁵,⁶
(¹ Engelhardt Institute of Molecular Biology, Moscow, Russia; ² Gamaleya Research Center of Epidemiology and Microbiology, Moscow, Russia; ³ Karolinska Institutet, Stockholm, Sweden; ⁴ Pirogov Medical State University, Moscow, Russia; ⁵ Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences, Moscow, Russia; ⁶ Riga Stradins University, Riga, Latvia)

Poster 105
‘Developing and improving vaccine delivery technologies’
Ivo Ploemen
(Institute for Translational Vaccinology (Intravacc), Bilthoven, The Netherlands)

Poster 106
‘Comparative study of different dissolving microneedle manufacture methods in skin vaccination focused on functional activity and stability of antigen’
Geonwoo Kang¹, Huisuk Yang¹, Mingyu Jang²,², Chisong Lee¹, Suyong Kim³,³, Shayan F. Lahijii and Hyungil Jung³,²
(¹ Yonsei University, Seoul, Republic of Korea; ² Juvic Inc., Yonsei Engineering Research Park, Seoul, Republic of Korea)

Poster 107
‘Tuberculin skin test with an implantation of hyaluronic acid dissolving microneedles encapsulating tuberculin purified protein derivatives’
Huisuk Yang¹, Mingyu Jang¹,², Geonwoo Kang¹, Suyong Kim³,³, Shayan F. Lahijii and Hyungil Jung³,²
(¹ Yonsei University, Seoul, Republic of Korea; ² Juvic Inc., Yonsei Engineering Research Park, Seoul, Republic of Korea)

Poster 108
‘Intradermal administration of HBV pp65 eVLPs is associated with slow clearance from the site of injection but no accumulation in major perfused tissues’
David E. Anderson, Marc Kirchmeier, Anne-Catherine Fluckiger, Catalina Soare, Umar Iqbal, Adam Asselin, Katie Sullivan, Julie Joseph and Tanvir Ahmed
(VBI Vaccines Inc., Ottawa, Ontario, Canada)

Poster 109
‘Administration of different Toll like receptor agonists by dissolving microneedle patches to pigs: Assessment of local immune response by macroscopic and histologic evaluation’
Sandra Vreman¹, Joanne McCafferey¹, Norbert Stockhofe-Zurwieden¹ and Anne Moore³
(¹ Wageningen Bioveterinary Research, Wageningen University & Research, The Hague, The Netherlands; ² Xeolas, Pharmaceuticals, Dublin, Ireland; ³ School of Pharmacy University College Cork, Cork, Ireland)

Poster 110
‘Novel MicroArray Patch Manufacturing System (MAP MS)’
Daniel R. Henderson, Milo Careaga, Nadine Bauer and Thomas Ellison
(Verdant Inc. Sacramento, California, USA)

Poster 111
‘Considerations for skin immunization using patch technology’
L. Smith¹, A. Rumyantsev², P. Vacus³, C. Fouquet-Dubois³ and E. Romeyer⁴
(Sanofi Pasteur, ¹ Toronto, Canada and ² Cambridge, U.S.A.; ³ Val-de-Reuil France, ⁴ Lyon, France)

The SVS 2017 Scientific Advisory Panel and the organizers would like to acknowledge the support of the following sponsors: